A phase I dose-escalation study of LBH589 administered orally in adult patients with advanced solid tumors or cutaneous T-cell lymphoma.

Trial Profile

A phase I dose-escalation study of LBH589 administered orally in adult patients with advanced solid tumors or cutaneous T-cell lymphoma.

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Nov 2012

At a glance

  • Drugs Panobinostat (Primary)
  • Indications Cutaneous T cell lymphoma; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 24 Mar 2010 Actual patient number (14) added as reported by ClinicalTrials.gov.
    • 24 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 24 Mar 2010 Actual end date (May 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top